Aim: To evaluate the efficacy of anti-angiogenic agent Bevacizumab in central retinal venous occlusion treatment.
Objectives: To determine the efficacy of Bevacizumab and ophthalmological parameters such as best corrected visual acuity (BCVA) and central macular thickness (CMT) using optical coherence tomography (OCT) in central retinal venous occlusion in patients aged less than 30.
Methods: This is a prospective, interventional study, done on 25 eyes of 25 patients aged 30 years and below with central retinal venous occlusion, who received intravitreal Bevacizumab injections for three consecutive months. The mean change in best corrected visual acuity (BCVA), and central macular thickness (CMT) measured by optical coherence tomography were compared and correlated at baseline after 3 months and 6 months follow-up.
Results: The mean best corrected visual acuity and the central macular thickness on OCT improved significantly from 1.08±0.29 and 454.80±114.5µm at baseline to 0.77±0.32 logMAR units and 339.7±82.5µm after 6 months follow up.
Conclusion: The current study showed that intravitreal Bevacizumab at a dose of 1.25 mg and with strict control of systemic contributory parameters seemed to improve BCVA and CMT and macular edema measured at baseline to 3 months and 6 months follow-up after three consecutive monthly injections.
Keywords: BCVA = Best corrected visual acuity; CMT = Central macular thickness; IVA = intravitreal Avastin; OCT = Optical coherence tomography; best corrected visual acuity (BCVA); central macular edema; central macular thickness (CMT); central retinal venous occlusion.
© 2024 The Authors.